Skip to main content

Smart bra can detect breast cancer

 

Clinical courses

 

Clinical courses

A French-Swiss consortium is conducting exploratory research to develop a“smart  bra”  for  detecting  breast  cancer.  It  wants  to  leverage  technological  progress  to  offer  a  more  accessible  diagnostic  method  than  mammography.  This  initiative  –  that  involves  five  partners  –  is supported in France by the FEDER (European fund for regional development) and in Switzerland by the Confederation  and  the  canton  of  Neuchâtel  within  the  framework  of  the  European  program  for  regional cooperation Interreg France-Switzerland.

According  to  the  GLOBOCAN  database,  throughout  2018  breast  cancer  was  the  main  cause  of  cancer-related deaths in women worldwide - with a million new diagnosed cases and approx. 627,000 deaths. French  statistics  in  2017  painted  a  similar  picture,  with  this  form  of  cancer  cited  as the  reason  behind  11, 883 deaths and 59,000 new cases. The Swiss estimates,  published for 2018, further described 6000 new  cases  of  invasive  cancer,  with 1372  deaths  over that  period;  equating  to  the  main  cause  of  Swiss female  mortality  between  the  ages  of  40  –  50  years.  But  these  difficult  statics  needn’t  be  so  -  whendetected early, this form of pathology can often be cured in more than 90% of cases.

Interpretation of a mammogram by the radiologist
(copyright Service communication – HNFC - juin 2019)

Mammography – an efficient method, but onerous and costly
Currently, breast cancer prevention methods in France and Switzerland rely on patient’s individual and/or organized screening. Most commonly, mammography is used to assess patients’ health, and presently it still remains the most effective and scientifically proven method to detect cancerous tissues. However, despite this technique’s effectiveness it comes with various barriers, including: access to care, the uncomfortable nature of the technique, and availability of appointments. Moreover, this method is expensive, requiring it to be performed by specialized doctors, which rules it out for large-scale screening programs in some countries. Therefore, the development of new screening method is a major need and issue within the public health sector.

The SBra project aims to study the feasibility of a solution combining non-invasive and non-intrusive technologies, based on the measurement of electrical and thermal properties of the mammary tissues. The ultimate objective is to design an effective, comfortable, portable and personalized system that is not only capable of detecting early stage breast cancer, but poses no risk to human health - and what better way to achieve these needs, than by creating the system in the form of something most woman are highly familiar with – the humble bra.

Easier access to screening
The SBra project aims to develop an intelligent bra, equipped with sensors, capable of effectively detecting this cancer early, comfortably and without risk to health. The device would be intended primarily for women considered to be at high risk, not those who are scheduled for a routine screening or check-up.

The project relies on French-Swiss cooperation involving: CSEM (Neuchâtel – CH), the Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM Besançon – F), the Hôpital Nord Franche- Comté (HNFC Belfort – F), the Université de Technologie de Belfort-Montbéliard (UTBM Belfort – F), and the company ZTC Technology (La Chaux-de-Fonds – CH). The teams are made up of around twenty people in France and around ten in Switzerland, including experts in Engineering, IT, Medicine, Philosophy and Sociology, as well as Clinical Research Coordinators.

The project was selected within the framework of the French-Swiss Interreg European territorial cooperation program for a duration of 24 months, with a budget of € 991,000 (CHF 1,102,000). It also benefits from financial support from the European Union via the European fund for regional development FEDER (€ 321,000 / CHF 383,000), the Swiss Confederation (€ 142,700 / CHF 158,500) and the canton of Neuchâtel (€ 140,900 / CHF 156,500).

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email